Literature DB >> 8676887

Generation of a variant of human interleukin-4 by alternative splicing.

W J Alms1, S P Atamas, V V Yurovsky, B White.   

Abstract

A second species of interleukin-4 (IL-4) mRNA was identified using both a reverse transcription-polymerase chain reaction and an RNase protection assay. This novel IL-4 mRNA was 48 base pairs smaller than IL-4 mRNA, which is the size of IL-4 exon 2. Sequence data of cloned cDNA demonstrated that this variant contained IL-4 exons 1,3 and 4, with exon 1 spliced directly to exon 3 in an open reading frame. The entire protein encoding region of this variant, named IL-4 delta 2, was identical to IL-4 except for the omission of exon 2. IL-4 delta 2 mRNA was detected in all human peripheral blood mononuclear cells tested and in purified CD3+ T cells. Amounts of both IL-4 and IL-4 delta 2 mRNAs increased upon T cell activation, although IL-4 mRNA increased to a greater extent than IL-4 delta 2 mRNA did. Human IL-3, IL-5, IL-13, and granulocyte macrophage-colony stimulating factor did not use alternative splicing to delete exon 2. We speculate that IL-4 delta 2 may regulate IL-4 function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676887     DOI: 10.1016/0161-5890(95)00154-9

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  13 in total

Review 1.  Interleukin 4 in systemic sclerosis: not just an increase.

Authors:  S P Atamas; B White
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 3.  The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals--a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

4.  Natural production and functional effects of alternatively spliced interleukin-4 protein in asthma.

Authors:  Irina G Luzina; Virginia Lockatell; Sachin Lavania; Edward M Pickering; Phillip H Kang; Yulia N Bashkatova; Sergey M Andreev; Sergei P Atamas
Journal:  Cytokine       Date:  2012-01-15       Impact factor: 3.861

5.  Splice isoforms of human interleukin-4 are functionally active in mice in vivo.

Authors:  Irina G Luzina; Virginia Lockatell; Nevins W Todd; Achsah D Keegan; Jeffrey D Hasday; Sergei P Atamas
Journal:  Immunology       Date:  2011-01-10       Impact factor: 7.397

6.  Splice variants of mda-7/IL-24 differentially affect survival and induce apoptosis in U2OS cells.

Authors:  Erin L Whitaker; Valery Filippov; Maria Filippova; Christian F Guerrero-Juarez; Penelope J Duerksen-Hughes
Journal:  Cytokine       Date:  2011-08-16       Impact factor: 3.861

7.  Increased levels of alternatively spliced interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis.

Authors:  L I Sakkas; C Tourtellotte; S Berney; A R Myers; C D Platsoucas
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

8.  Comparative cytokine gene expression: regulation and release by human mast cells.

Authors:  A Möller; B M Henz; A Grützkau; U Lippert; Y Aragane; T Schwarz; S Krüger-Krasagakes
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

Review 9.  Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn.

Authors:  Nicole M Martinez; Kristen W Lynch
Journal:  Immunol Rev       Date:  2013-05       Impact factor: 12.988

10.  Tuberculosis-induced variant IL-4 mRNA encodes a cytokine functioning as growth factor for (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-specific Vgamma2Vdelta2 T cells.

Authors:  ZhuQing Yuan; Richard Wang; Yuyang Lee; Crystal Y Chen; XingBing Yu; ZhongDao Wu; Dan Huang; Ling Shen; Zheng W Chen
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.